Clinical Trial

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Name: To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis — clinical trial record (NCT07629583)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-08

Trial Details

NCT Number	NCT07629583
Lead Sponsor	Genentech, Inc.
Conditions	Lupus Erythematosus, Systemic
Enrollment	46 participants
Start Date	2026-10-31
Primary Completion	2030-03-29 (estimated)
Study Completion	2030-03-29 (estimated)
Updated on ClinicalTrials.gov	2026-08-07